The Currency analytics
By James Thorp
Margex just rolled out five fresh trading pairs, giving users more ways to leverage trade up to 100x on trending tokens.
The move bumps Margex's total trading pairs past 50, part of what CEO John Smith calls a push to stay competitive in the fast-moving crypto market.
TradingView integration changed everything.
The partnership with TradingView brings serious firepower to Margex's charting game. Over 80 million traders worldwide use TradingView's tools, which pack more than 100 technical…
Margex didn't stop there. Partnerships with payment providers Paybis and FinchPay opened doors to more than 50 cryptocurrencies and 40 fiat currencies on the platform.
Founded back in 2019, Margex built its reputation as a boutique crypto exchange focused on secure, user-friendly copy trading.
The platform stays active on social media through Facebook, Twitter, Telegram, and YouTube channels.
But Margex keeps future plans under wraps. Company reps said current expansions focus on user experience and trading options, but they won't spill details about what's coming next.
Industry watchers think Margex's emphasis on user-friendly interfaces and broad currency options could shake up competition among exchanges.
Adding tokens like BIO Protocol and Pudgy Penguins shows Margex wants to capture niche markets within crypto.
Market analysts note that Margex's latest updates aim to differentiate it from competitors in the crowded cryptocurrency exchange space.
The educational component matters too. Margex provides resources and tools to help users, especially newcomers, navigate crypto trading complexities.
Payment flexibility through Paybis and FinchPay partnerships addresses a major pain point for crypto traders.
Margex's PR team handles media inquiries at pr@margex.com, though they haven't released specifics about upcoming features or expansion timelines.
Trading volume data for the new pairs hasn't been released yet. Early adoption metrics for BIO Protocol, Kaito, Metis, Pudgy Penguins, and ZKsync trading remain under review as…